FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic ca

[News]

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

More... (http://www.news-medical.net/news/20110123/FibroGen-announces-FG-3019-interim-results-from-phase-12-trial-against-pancreatic-cancer.aspx)